Search Results - "Huat Tan, Eng"

Novel therapeutic targets on the horizon for lung cancer by Tan, Wan-Ling, MRCP, Jain, Amit, MMed, Takano, Angela, MD, Newell, Evan W, PhD, Iyer, N Gopalakrishna, MD, Lim, Wan-Teck, MRCP, Tan, Eng-Huat, MMed, Zhai, Weiwei, PhD, Hillmer, Axel M, PhD, Tam, Wai-Leong, PhD, Tan, Daniel S W, Dr

“…Summary Lung cancer is a leading cause of cancer-related mortality worldwide, and is classically divided into two major histological subtypes: non-small-cell…”
Get full text

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial by Park, Keunchil, Prof, Tan, Eng-Huat, MD, O'Byrne, Ken, Prof, Zhang, Li, Prof, Boyer, Michael, Prof, Mok, Tony, Prof, Hirsh, Vera, Prof, Yang, James Chih-Hsin, Prof, Lee, Ki Hyeong, MD, Lu, Shun, Prof, Shi, Yuankai, MD, Kim, Sang-We, MD, Laskin, Janessa, MD, Kim, Dong-Wan, Prof, Arvis, Catherine Dubos, MD, Kölbeck, Karl, MD, Laurie, Scott A, MD, Tsai, Chun-Ming, Prof, Shahidi, Mehdi, MD, Kim, Miyoung, MD, Massey, Dan, PhD, Zazulina, Victoria, MD, Paz-Ares, Luis, MD

“…Summary Background The irreversible ErbB family blocker afatinib and the reversible EGFR tyrosine kinase inhibitor gefitinib are approved for first-line…”
Get full text

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial by Miller, Vincent A, Prof, Hirsh, Vera, MD, Cadranel, Jacques, Prof, Chen, Yuh-Min, MD, Park, Keunchil, Prof, Kim, Sang-We, Prof, Zhou, Caicun, Prof, Su, Wu-Chou, Prof, Wang, Mengzhao, Prof, Sun, Yan, Prof, Heo, Dae Seog, Prof, Crino, Lucio, Prof, Tan, Eng-Huat, MD, Chao, Tsu-Yi, Prof, Shahidi, Mehdi, MD, Cong, Xiuyu Julie, PhD, Lorence, Robert M, MD, Yang, James Chih-Hsin, Prof

“…Summary Background Afatinib, an irreversible ErbB-family blocker, has shown preclinical activity when tested in EGFR mutant models with mutations that confer…”
Get full text

Detection of circulating tumor DNA with ultradeep sequencing of plasma cell‐free DNA for monitoring minimal residual disease and early detection of recurrence in early‐stage lung cancer by Tan, Aaron C., Lai, Gillianne G. Y., Saw, Stephanie P. L., Chua, Kevin L. M., Takano, Angela, Ong, Boon‐Hean, Koh, Tina P. T., Jain, Amit, Tan, Wan Ling, Ng, Quan Sing, Kanesvaran, Ravindran, Rajasekaran, Tanujaa, Kalashnikova, Ekaterina, Renner, Derrick, Sudhaman, Sumedha, Malhotra, Meenakshi, Sethi, Himanshu, Liu, Minetta C., Aleshin, Alexey, Lim, Wan‐Teck, Tan, Eng‐Huat, Skanderup, Anders J., Ang, Mei‐Kim, Tan, Daniel S. W.

“…Background In early‐stage non–small cell lung cancer (NSCLC), recurrence is frequently observed. Circulating tumor DNA (ctDNA) has emerged as a noninvasive…”
Get full text

Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing by Nahar, Rahul, Zhai, Weiwei, Zhang, Tong, Takano, Angela, Khng, Alexis J., Lee, Yin Yeng, Liu, Xingliang, Lim, Chong Hee, Koh, Tina P. T., Aung, Zaw Win, Lim, Tony Kiat Hon, Veeravalli, Lavanya, Yuan, Ju, Teo, Audrey S. M., Chan, Cheryl X., Poh, Huay Mei, Chua, Ivan M. L., Liew, Audrey Ann, Lau, Dawn Ping Xi, Kwang, Xue Lin, Toh, Chee Keong, Lim, Wan-Teck, Lim, Bing, Tam, Wai Leong, Tan, Eng-Huat, Hillmer, Axel M., Tan, Daniel S. W.

“…EGFR -mutant lung adenocarcinomas (LUAD) display diverse clinical trajectories and are characterized by rapid but short-lived responses to EGFR tyrosine kinase…”
Get full text

Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis by Tan, Aaron C., Lai, Gillianne G.Y., Tan, Gek San, Poon, Shou Yu, Doble, Brett, Lim, Tse Hui, Aung, Zaw Win, Takano, Angela, Tan, Wan Ling, Ang, Mei-Kim, Tan, Bien Soo, Devanand, Anantham, Too, Chow Wei, Gogna, Apoorva, Ong, Boon-Hean, Koh, Tina P.T., Kanesvaran, Ravindran, Ng, Quan Sing, Jain, Amit, Rajasekaran, Tanujaa, Lim, Alvin S.T., Lim, Wan Teck, Toh, Chee Keong, Tan, Eng-Huat, Lim, Tony Kiat Hon, Tan, Daniel S.W.

“…•Upfront NGS is feasible and cost-effective in an EGFR mutant predominant population.•Characterizing the wider genomic profile may yield important…”
Get full text

Phase II study of nimotuzumab (TheraCim‐hR3) concurrent with cisplatin/radiotherapy in patients with locally advanced head and neck squamous cell carcinoma by Ang, Mei‐Kim, Montoya, Jose Enrique, Tharavichitkul, Ekkasit, Lim, Cindy, Tan, Terence, Wang, Lan Ying, Wee, Joseph, Soong, Yoke‐Lim, Fong, Kam‐Weng, Ng, Quan Sing, Tan, Daniel Shao‐Weng, Toh, Chee‐Keong, Tan, Eng‐Huat, Lim, Wan‐Teck

“…Background The efficacy of a combination of nimotuzumab, a humanized monoclonal antibody to the epidermal growth factor receptor, with chemoradiation in…”
Get full text

Clinical efficacy and biomarker analysis of dual PD-1/CTLA-4 blockade in recurrent/metastatic EBV-associated nasopharyngeal carcinoma by Lim, Darren Wan-Teck, Kao, Hsiang-Fong, Suteja, Lisda, Li, Constance H., Quah, Hong Sheng, Tan, Daniel Shao-Weng, Tan, Sze-Huey, Tan, Eng-Huat, Tan, Wan-Ling, Lee, Justina Nadia, Wee, Felicia Yu-Ting, Jain, Amit, Goh, Boon-Cher, Chua, Melvin L. K., Liao, Bin-Chi, Ng, Quan Sing, Hong, Ruey-Long, Ang, Mei-Kim, Yeong, Joe Poh-Sheng, Iyer, N. Gopalakrishna

“…Single-agent checkpoint inhibitor (CPI) activity in Epstein-Barr Virus (EBV) related nasopharyngeal carcinoma (NPC) is limited. Dual CPI shows increased…”
Get full text

First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression by Schuler, Martin, Tan, Eng-Huat, O’Byrne, Kenneth, Zhang, Li, Boyer, Michael, Mok, Tony, Hirsh, Vera, Yang, James Chih-Hsin, Lee, Ki Hyeong, Lu, Shun, Shi, Yuankai, Kim, Sang-We, Laskin, Janessa, Kim, Dong-Wan, Arvis, Catherine Dubos, Kölbeck, Karl, Massey, Dan, Märten, Angela, Paz-Ares, Luis, Park, Keunchil

“…Purpose In the randomized phase IIb LUX-Lung 7 trial, afatinib significantly improved progression-free survival (PFS) and time-to-treatment failure vs…”
Get full text

Never-Smokers With Lung Cancer: Epidemiologic Evidence of a Distinct Disease Entity by TOH, Chee-Keong, FEI GAO, TAN, Eng-Huat, LIM, Wan-Teck, LEONG, Swan-Swan, PONG, Kam-Weng, YAP, Swee-Peng, HSU, Anne A. L, ENG, Philip, KOONG, Heng-Nung, THIRUGNANAM, Agasthian

“…Tobacco smoke is a definite causative agent for lung cancer. It is increasingly being recognized that never-smokers can be afflicted with non-small-cell lung…”
Get full text

Human Innate Lymphoid Cell Subsets Possess Tissue-Type Based Heterogeneity in Phenotype and Frequency by Simoni, Yannick, Fehlings, Michael, Kløverpris, Henrik N., McGovern, Naomi, Koo, Si-Lin, Loh, Chiew Yee, Lim, Shawn, Kurioka, Ayako, Fergusson, Joannah R., Tang, Choong-Leong, Kam, Ming Hian, Dennis, Koh, Lim, Tony Kiat Hon, Fui, Alexander Chung Yaw, Hoong, Chan Weng, Chan, Jerry Kok Yen, Curotto de Lafaille, Maria, Narayanan, Sriram, Baig, Sonia, Shabeer, Muhammad, Toh, Sue-Anne Ee Shiow, Tan, Henry Kun Kiaang, Anicete, Rosslyn, Tan, Eng-Huat, Takano, Angela, Klenerman, Paul, Leslie, Alasdair, Tan, Daniel S.W., Tan, Iain Beehuat, Ginhoux, Florent, Newell, Evan W.

“…Animal models have highlighted the importance of innate lymphoid cells (ILCs) in multiple immune responses. However, technical limitations have hampered…”
Get full text

Landscape of germline pathogenic variants in patients with dual primary breast and lung cancer by Lee, Ning-Yuan, Hum, Melissa, Zihara, Sabna, Wang, Lanying, Myint, Matthew K, Lim, Darren Wan-Teck, Toh, Chee-Keong, Skanderup, Anders, Samol, Jens, Tan, Min-Han, Ang, Peter, Lee, Soo-Chin, Tan, Eng-Huat, Lai, Gillianne G Y, Tan, Daniel S W, Yap, Yoon-Sim, Lee, Ann S G

“…Cancer predisposition is most often studied in the context of single cancers. However, inherited cancer predispositions can also give rise to multiple primary…”
Get full text

Phase III Trial Comparing Vinflunine With Docetaxel in Second-Line Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy by KRZAKOWSKI, Maciej, RAMLAU, Rodryg, DELGADO, François M, SALHI, Yacine, VAISSIERE, Nathalie, HANSEN, Olfred, TAN, Eng-Huat, QUOIX, Elisabeth, GARRIDO, Pilar, DOUILLARD, Jean-Yves, JASSEM, Jacek, SZCZESNA, Aleksandra, ZATLOUKAL, Petr, VON PAWEL, Joachim, XUSHAN SUN, BENNOUNA, Jaafar, SANTORO, Armando, BIESMA, Bonne

“…To compare vinflunine (VFL) to docetaxel in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC) who have experienced treatment failure with…”
Get full text

The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients by Chew, Sin-Chi, Singh, Onkar, Chen, Xiangai, Ramasamy, Rathi Devi, Kulkarni, Tejal, Lee, Edmund J. D., Tan, Eng-Huat, Lim, Wan-Teck, Chowbay, Balram

“…Purpose This exploratory study aimed to explain the interindividual variabilities of docetaxel pharmacokinetics and pharmacodynamics in Asian nasopharyngeal…”
Get full text

A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China by Tu, Hai-Yan, Feng, Jifeng, Shi, Meiqi, Zhao, Jun, Wang, Yuyan, Chang, Jianhua, Wang, Jialei, Cheng, Ying, Zhu, Jing, Tan, Eng-Huat, Li, Kai, Zhang, Yiping, Lee, Victor, Yang, Cheng-Ta, Su, Wu-Chou, Lam, David Chi-Leung, Srinivasa, B. J., Rajappa, Senthil, Ho, Ching-Liang, Lam, Kwok Chi, Hu, Yi, Bondarde, Shailesh Arjun, Liu, Xiaoqing, Tian, Yahui, Xue, Zhiyi, Cseh, Agnieszka, Huang, Dennis Chin-Lun, Zhou, Caicun, Wu, Yi-Long

“…Background Afatinib has been shown as a suitable option for the treatment of epidermal growth factor receptor mutation-positive ( EGFR m+) non-small-cell lung…”
Get full text

Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC by Tan, Eng‐Huat, Lim, Wan‐Teck, Ahn, Myung‐Ju, Ng, Quan‐Sing, Ahn, Jin Seok, Shao‐Weng Tan, Daniel, Sun, Jong‐Mu, Han, May, Payumo, Francis C., McKee, Krista, Yin, Wei, Credi, Marc, Agarwal, Shefali, Jac, Jaroslaw, Park, Keunchil

“…Hepatocyte growth factor (HGF)/c‐Met pathway dysregulation is a mechanism for epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)…”
Get full text

A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer by Soh, Sheila X, Siddiqui, Fahad J, Allen, John C, Kim, Go Woon, Lee, Jae Cheol, Yatabe, Yasushi, Soda, Manabu, Mano, Hiroyuki, Soo, Ross A, Chin, Tan-Min, Ebi, Hiromichi, Yano, Seiji, Matsuo, Keitaro, Niu, Xiaomin, Lu, Shun, Isobe, Kazutoshi, Lee, Jih-Hsiang, Yang, James C, Zhao, Mingchuan, Zhou, Caicun, Lee, June-Koo, Lee, Se-Hoon, Lee, Ji Yun, Ahn, Myung-Ju, Tan, Tira J, Tan, Daniel S, Tan, Eng-Huat, Ong, S Tiong, Lim, Wan-Teck

“…A germline deletion in the BIM (BCL2L11) gene has been shown to impair the apoptotic response to tyrosine kinase inhibitors (TKIs) in vitro but its association…”
Get full text

Interactions between clinical factors, p16, and cyclin-D1 expression and survival outcomes in oropharyngeal and hypopharyngeal squamous cell carcinoma by Ang, Siok-Hoon, Haaland, Benjamin, Acharyya, Sanchalika, Thu, Minn M. M., Krisna, Sai-Sakktee, Hwang, Siok-Gek, Tan, Puay-Hoon, Ng, Quan-Sing, Tan, Daniel S. W., Tai, Wai-Meng, Tan, Eng-Huat, Lim, Wan-Teck, Ang, Mei-Kim

“…Background P16 and cyclin‐D1 are cell cycle proteins commonly dysregulated in head and neck carcinoma. We assessed their expression, clinicopathological…”
Get full text

Pharmacogenetics of SLCO1B1 gene and the impact of 1b and 15 haplotypes on irinotecan disposition in Asian cancer patients by Xiang, Xiaoqiang, Rao Jada, Srinivasa, Hua Li, Hui, Fan, Lu, San Tham, Lai, Ing Wong, Chiung, Chin Lee, Soo, Lim, Robert, Yu Zhou, Qing, Cher Goh, Boon, Huat Tan, Eng, Chowbay, Balram

“…OBJECTIVETo investigate the pharmacogenetic effect of SLCO1B1 *1a, *1b, *5 and *15 polymorphisms on irinotecan disposition in Asian cancer patients…”
Get full text

Methionine is a metabolic dependency of tumor-initiating cells by Wang, Zhenxun, Yip, Lian Yee, Lee, Jia Hui Jane, Wu, Zhengwei, Chew, Hui Yi, Chong, Pooi Kiat William, Teo, Chin Chye, Ang, Heather Yin-Kuan, Peh, Kai Lay Esther, Yuan, Ju, Ma, Siming, Choo, Li Shi Kimberly, Basri, Nurhidayah, Jiang, Xia, Yu, Qiang, Hillmer, Axel M., Lim, Wan Teck, Lim, Tony Kiat Hon, Takano, Angela, Tan, Eng Huat, Tan, Daniel Shao Weng, Ho, Ying Swan, Lim, Bing, Tam, Wai Leong

“…Understanding cellular metabolism holds immense potential for developing new classes of therapeutics that target metabolic pathways in cancer. Metabolic…”
Get full text